Professor Lars Lannfelt Honored with Notable Prize
BioArctic AB (publ) is thrilled to announce that its founder, Professor Lars Lannfelt, has been awarded the prestigious 2025 Hartwig Piepenbrock-DZNE Prize. This esteemed recognition celebrates his significant contributions to the field of Alzheimer's disease research, particularly in the advancement of lecanemab, a drug that showcases promise in treating this debilitating condition.
Impact on Alzheimer’s Research
In an inspiring statement, Professor Lannfelt expressed his pride in receiving this honor. "It has always been my mission to instill hope and advance treatments for those impacted by Alzheimer’s disease. My dedication is driven by the desire to make a difference in patients’ lives," he remarked. The ongoing evolution of Alzheimer's research is remarkable, as evidenced by lecanemab's benefits observed in the global Phase 3 Clarity AD trial. This trial utilized gold standard measures to assess its effectiveness.
Scientific Contributions that Matter
Professor Lannfelt's journey began in 2003 when he co-founded BioArctic with Pär Gellerfors. Their goal was to develop a groundbreaking antibody treatment informed by Lannfelt's early discoveries regarding amyloid-beta protein's role in Alzheimer's disease. Lecanemab, developed in partnership with Eisai, targets specific forms of this protein to facilitate its removal from the brain, thereby altering the disease's progression.
A Legacy of Recognition
Since its inception in 2011, the Hartwig Piepenbrock-DZNE Prize has been awarded every two years to celebrate remarkable research in neurodegenerative disorders. This prize honors the legacy of Hartwig Piepenbrock, a former CEO and Chairman of the Piepenbrock Group, whose life was affected by dementia. An international committee, coordinated by the German Center for Neurodegenerative Diseases (DZNE), selects the prize winners. With this award, Professor Lannfelt joins a select group of esteemed researchers who have made significant impacts in this crucial field.
Looking Toward the Future
The future of Alzheimer's disease treatment is becoming increasingly optimistic. Professor Lannfelt highlighted that the strides made in this domain, combined with the introduction of advanced diagnostic techniques, signal a potential paradigm shift. He is optimistic that we may not only slow down disease progression but potentially halt it altogether.
About BioArctic
BioArctic AB is a leading Swedish biopharmaceutical company devoted to creating innovative treatments aimed at delaying or preventing the progression of neurodegenerative diseases. The firm is recognized for developing Leqembi, known as lecanemab, which is the first drug to demonstrate a reduction in cognitive decline in patients with early Alzheimer's disease. BioArctic maintains a broad research scope, tackling Alzheimer’s, Parkinson’s, ALS, and various enzyme deficiency diseases. The company employs its proprietary BrainTransporter technology to enhance drug delivery into the brain, marking important advancements in treatment efficacy.
Contact Information
For more information, please reach out to Oskar Bosson, VP Communications and IR. He can be contacted through phone at +46 70 410 71 80.
Frequently Asked Questions
What is the Hartwig Piepenbrock-DZNE Prize?
The Hartwig Piepenbrock-DZNE Prize is awarded to researchers for their outstanding contributions in the field of neurodegenerative diseases.
Who is Lars Lannfelt?
Professor Lars Lannfelt is the founder of BioArctic AB and has been instrumental in Alzheimer’s research and development of lecanemab.
What is lecanemab?
Lecanemab is an antibody treatment developed to target and clear amyloid-beta proteins from the brain, aiming to alter the course of Alzheimer's disease.
How often is the Hartwig Piepenbrock-DZNE Prize awarded?
The prize is awarded every two years since its establishment in 2011, honoring significant research achievements.
What is the future of Alzheimer's treatment?
The future is hopeful, with advancements in research indicating potential for treatments that could either slow down or halt the progression of Alzheimer's disease.
